Koji Matsuo1,2,3, Robert Dalton Chavez1,2,3, Emilie Barruet1,2,3, Edward C Hsiao4,5,6. 1. Division of Endocrinology and Metabolism, University of California, 513 Parnassus Ave., HSE901, San Francisco, CA, 94143-0794, USA. 2. Department of Medicine, The Institute for Human Genetics, University of California, CA, San Francisco, USA. 3. The Program in Craniofacial Biology, University of California, CA, San Francisco, USA. 4. Division of Endocrinology and Metabolism, University of California, 513 Parnassus Ave., HSE901, San Francisco, CA, 94143-0794, USA. Edward.hsiao@ucsf.edu. 5. Department of Medicine, The Institute for Human Genetics, University of California, CA, San Francisco, USA. Edward.hsiao@ucsf.edu. 6. The Program in Craniofacial Biology, University of California, CA, San Francisco, USA. Edward.hsiao@ucsf.edu.
Abstract
PURPOSE OF REVIEW: Heterotopic ossification (HO) is associated with inflammation. The goal of this review is to examine recent findings on the roles of inflammation and the immune system in HO. We examine how inflammation changes in fibrodysplasia ossificans progressiva, in traumatic HO, and in other clinical conditions of HO. We also discuss how inflammation may be a target for treating HO. RECENT FINDINGS: Both genetic and acquired forms of HO show similarities in their inflammatory cell types and signaling pathways. These include macrophages, mast cells, and adaptive immune cells, along with hypoxia signaling pathways, mesenchymal stem cell differentiation signaling pathways, vascular signaling pathways, and inflammatory cytokines. Because there are common inflammatory mediators across various types of HO, these mediators may serve as common targets for blocking HO. Future research may focus on identifying new inflammatory targets and testing combinatorial therapies based on these results.
PURPOSE OF REVIEW: Heterotopic ossification (HO) is associated with inflammation. The goal of this review is to examine recent findings on the roles of inflammation and the immune system in HO. We examine how inflammation changes in fibrodysplasia ossificans progressiva, in traumatic HO, and in other clinical conditions of HO. We also discuss how inflammation may be a target for treating HO. RECENT FINDINGS: Both genetic and acquired forms of HO show similarities in their inflammatory cell types and signaling pathways. These include macrophages, mast cells, and adaptive immune cells, along with hypoxia signaling pathways, mesenchymal stem cell differentiation signaling pathways, vascular signaling pathways, and inflammatory cytokines. Because there are common inflammatory mediators across various types of HO, these mediators may serve as common targets for blocking HO. Future research may focus on identifying new inflammatory targets and testing combinatorial therapies based on these results.
Authors: Emilie Barruet; Blanca M Morales; Corey J Cain; Amy N Ton; Kelly L Wentworth; Tea V Chan; Tania A Moody; Mariëlle C Haks; Tom Hm Ottenhoff; Judith Hellman; Mary C Nakamura; Edward C Hsiao Journal: JCI Insight Date: 2018-11-15
Authors: Shailesh Agarwal; Shawn Loder; Cameron Brownley; David Cholok; Laura Mangiavini; John Li; Christopher Breuler; Hsiao H Sung; Shuli Li; Kavitha Ranganathan; Joshua Peterson; Ronald Tompkins; David Herndon; Wenzhong Xiao; Dolrudee Jumlongras; Bjorn R Olsen; Thomas A Davis; Yuji Mishina; Ernestina Schipani; Benjamin Levi Journal: Proc Natl Acad Sci U S A Date: 2015-12-31 Impact factor: 11.205
Authors: Benjamin K Potter; Travis C Burns; Anton P Lacap; Robert R Granville; Donald A Gajewski Journal: J Bone Joint Surg Am Date: 2007-03 Impact factor: 5.284
Authors: Haitao Wang; Carter Lindborg; Vitali Lounev; Jung-Hoon Kim; Ruth McCarrick-Walmsley; Meiqi Xu; Laura Mangiavini; Jay C Groppe; Eileen M Shore; Ernestina Schipani; Frederick S Kaplan; Robert J Pignolo Journal: J Bone Miner Res Date: 2016-04-20 Impact factor: 6.741
Authors: Hsiao Hsin Sung Hsieh; Michael T Chung; Ronald M Allen; Kavitha Ranganathan; Joe Habbouche; David Cholok; Jonathan Butts; Arminder Kaura; Ramkumar Tiruvannamalai-Annamalai; Chris Breuler; Caitlin Priest; Shawn J Loder; John Li; Shuli Li; Jan Stegemann; Steven L Kunkel; Benjamin Levi Journal: Front Endocrinol (Lausanne) Date: 2017-04-24 Impact factor: 5.555
Authors: Kylie A Alexander; Hsu-Wen Tseng; Whitney Fleming; Beulah Jose; Marjorie Salga; Irina Kulina; Susan M Millard; Allison R Pettit; François Genêt; Jean-Pierre Levesque Journal: Front Immunol Date: 2019-03-07 Impact factor: 7.561
Authors: Ruben D de Ruiter; Bernard J Smilde; Gerard Pals; Nathalie Bravenboer; Petra Knaus; Ton Schoenmaker; Esmée Botman; Gonzalo Sánchez-Duffhues; Maurizio Pacifici; Robert J Pignolo; Eileen M Shore; Marjolein van Egmond; Hans Van Oosterwyck; Frederick S Kaplan; Edward C Hsiao; Paul B Yu; Renata Bocciardi; Carmen Laura De Cunto; Patricia Longo Ribeiro Delai; Teun J de Vries; Susanne Hilderbrandt; Richard T Jaspers; Richard Keen; Peter Koolwijk; Rolf Morhart; Jan C Netelenbos; Thomas Rustemeyer; Christiaan Scott; Clemens Stockklausner; Peter Ten Dijke; James Triffit; Francesc Ventura; Roberto Ravazzolo; Dimitra Micha; Elisabeth M W Eekhoff Journal: Front Endocrinol (Lausanne) Date: 2021-11-10 Impact factor: 6.055
Authors: Koji Matsuo; Abigail Lepinski; Robert D Chavez; Emilie Barruet; Ashley Pereira; Tania A Moody; Amy N Ton; Aditi Sharma; Judith Hellman; Kiichiro Tomoda; Mary C Nakamura; Edward C Hsiao Journal: Bone Date: 2021-07-24 Impact factor: 4.398
Authors: Sukhmani Singh; Joseph Kidane; Kelly L Wentworth; Daria Motamedi; Saam Morshed; Andrew E Schober; Edward C Hsiao Journal: BMC Musculoskelet Disord Date: 2020-04-03 Impact factor: 2.362